Disease · MONDO_0100313
Trials49
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
1 to 20 of 49
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03493685 | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | Phase 3 | 371 | 2024-04-30 | Focal Segmental Glomerulosclerosis | IRBESARTAN, SPARSENTAN | Its record names the disease | ClinicalTrials.gov |
| NCT01613118 | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Phase 2 | 109 | 2021-07-27 | Focal Segmental Glomerulosclerosis | IRBESARTAN, SPARSENTAN | Its record names the disease | ClinicalTrials.gov |
| NCT03366337 | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | Phase 2 | 103 | 2022-01-18 | IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney | BARDOXOLONE METHYL | Its record names the disease | ClinicalTrials.gov |
| NCT03536754 | A Study of CCX140-B in Subjects With FSGS | Phase 2 | 46 | 2023-12-05 | FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis | ILACIRNON | Its record names the disease | ClinicalTrials.gov |
| NCT02592798 | Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) | Phase 2 | 36 | 2021-03-05 | Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease | ABATACEPT | Its record names the disease | ClinicalTrials.gov |
| NCT00814255 | Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial | Phase 2 | 32 | 2016-07-11 | Focal Segmental Glomerulosclerosis | ADALIMUMAB, GALACTOSE | Its record names the disease | ClinicalTrials.gov |
| NCT01164098 | Rituximab to Prevent Recurrence of Proteinuria | Phase 3 | 30 | 2018-09-20 | FSGS, Proteinuria | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00001959 | Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) | Phase 2 | 21 | 2012-06-01 | Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria | PIRFENIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT02000440 | A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 | 17 | 2017-06-12 | Glomerulosclerosis, Focal Segmental | LOSMAPIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT04340362 | Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | Phase 2 | 16 | 2023-07-10 | Glomerulosclerosis, Focal Segmental | INAXAPLIN | Its record names the disease | ClinicalTrials.gov |
| NCT00007475 | Permeability Factor in Focal Segmental Glomerulosclerosis | Phase 1/2 | 15 | 2016-02-10 | Focal Segmental Glomerulosclerosis | CYCLOPHOSPHAMIDE, DEXAMETHASONE, PIRFENIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT00098020 | Podocyte Retinoids | Phase 2 | 12 | 2017-12-13 | Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental | ISOTRETINOIN | Its record names the disease | ClinicalTrials.gov |
| NCT01573533 | A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS | Phase 2 | 9 | 2020-02-10 | Primary Focal Segmental Glomerulosclerosis | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00065611 | Steroid Treatment for Kidney Disease | Phase 3 | 8 | 2011-10-28 | Nephrosis, Focal Lipoid Glomerulosclerosis | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT01113385 | Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome | Not applicable | 7 | 2014-09-15 | Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome | GALACTOSE | Its record names the disease | ClinicalTrials.gov |
| NCT04009668 | Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease | Phase 2 | 7 | 2024-10-30 | FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease | ADALIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03598036 | Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis | Phase 2 | 5 | 2021-09-16 | Focal Segmental Glomerulosclerosis | VOCLOSPORIN | Its record names the disease | ClinicalTrials.gov |
| NCT03703908 | A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome | Phase 2 | 5 | 2024-02-06 | Focal Segmental Glomerulosclerosis | ILACIRNON | Its record names the disease | ClinicalTrials.gov |
| NCT05183646 | A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB | Phase 3 | 286 | FSGS | REPAGERMANIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT06983028 | Atacicept in Multiple Glomerular Diseases | Phase 2 | 250 | pMN, IgAN, Nephrotic Syndrome, MCD, FSGS | ATACICEPT | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100313/trials